Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 to evaluate their safety and reactogenicity in Virologically-Suppressed Chronic Hepatitis B Participants

Next Previous
X
Search
Trial Profile

A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 to evaluate their safety and reactogenicity in Virologically-Suppressed Chronic Hepatitis B Participants

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imdusiran (Primary) ; Nivolumab (Primary) ; VTP 300 (Primary) ; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept
  • Acronyms IM-PROVE II
  • Sponsors Arbutus Biopharma

    • Most Recent Events

    • 06 Jun 2024 According to Barinthus Biotherapeutics media release, interim results from this study were presented at the European Association for the Study of the Liver (EASL) Congress 2024.
    • 06 Jun 2024 Interim Results (as of the data cutoff on April 12, 2024) presented in the Arbutus Biopharma Media Release.
    • 06 Jun 2024 According to an Arbutus Biopharma media release, company is looking forward to the data coming in the second half of this year from the additional arm of this trial evaluating the potential of nivolumab

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top